Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use AMONDYS 45® safely and effectively. See full prescribing information for AMONDYS 45. AMONDYS 45 (casimersen) injection, for intravenous useInitial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-prescription
AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45 [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.
- generic_name
- casimersen
- product_names
- casimersen
- ndc
- 60923-227, 60923-227-02
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en